Who are mRNA-1403's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): mRNA-1273, COVAX only (1st and 2nd dose), Comirnaty Original/Omicron BA.1, protein subunit: Novavax COVID-19 vaccine, Ad26.COV2.S vaccine, Novavax recombinant protein vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mrna-1403.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

mRNA-1403 — Competitive Intelligence Brief

mRNA-1403 (mRNA-1403) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Infectious Disease.

phase 3 mRNA vaccine SARS-CoV-2 spike protein Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

mRNA-1403 (mRNA-1403) — ModernaTX, Inc.. mRNA-1403 is an mRNA-based vaccine designed to encode for the SARS-CoV-2 spike protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
mRNA-1403 TARGET	mRNA-1403	ModernaTX, Inc.	phase 3	mRNA vaccine	SARS-CoV-2 spike protein
mRNA-1273	mRNA-1273	Assistance Publique - Hôpitaux de Paris	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Comirnaty Original/Omicron BA.1	Comirnaty Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
protein subunit: Novavax COVID-19 vaccine	protein subunit: Novavax COVID-19 vaccine	Novavax	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mRNA-1403 — Competitive Intelligence Brief. https://druglandscape.com/ci/mrna-1403. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab